Sana CEO Steve Harr actively questions whether the company's groundbreaking science can translate into a scalable, commercially viable therapy. This internal pressure focuses the team on solving not just the scientific challenges ("does it work?"), but also manufacturing ("can you scale it?") and the commercial model required for a true cure.

The CEO believes the most profound lessons in biotech come from speaking with founders of companies that did not succeed. In an industry defined by high clinical trial risk, understanding the missteps and navigating the challenges of unsuccessful ventures provides more practical wisdom than studying success stories alone.

Szabi Nagy's first startup failed by building a technically brilliant product for cryptography nerds that businesses didn't want. This taught him to focus his next company, Turbine, on solving the immediate problems of drug discovery scientists, rather than just developing advanced, 'wacky' science.

Progress in drug development often hides inside failures. A therapy that fails in one clinical trial can provide critical scientific learnings. One company leveraged insights from a failed study to redesign a subsequent trial, which was successful and led to the drug's approval.

When deciding on a risky, $100M clinical trial after a competitor failed, Cogent's team inverted their analysis. They actively searched for reasons the trial would *not* work. The inability to find a clear blocker provided the conviction to proceed, a strategy that ultimately paid off.

CEO Andy Robbins regrets being too slow and careful in building his research team, wishing he had been more aggressive from the start. His deference to a former employer's non-solicit agreement, which later proved moot when the site was shut down, cost his company valuable time and delayed key programs.

For mid-cap biotech companies, the market doesn't reward small wins in financial efficiency like beating earnings per share. Instead, value is created by developing breakthrough therapies. This belief leads Cogent's CEO to prioritize R&D speed over strict capital efficiency, as the ultimate prize is a game-changing drug.

To save money, Rhythm's leadership considered canceling a clinical study because the prevailing scientific logic suggested their drug wouldn't work. The study's unexpected, resounding success became the company's pivotal turning point, highlighting the value of pursuing scientifically contrarian ideas.

Peptilogics shifted from the challenging general antibiotic market to a niche with massive unmet needs after an orthopedic surgeon collaborator called their drug "the greatest thing I've ever seen" for prosthetic joint infections, an application the CEO hadn't even considered.